Skip to main content

Stopping dementia at the nose with combination of rifampicin and resveratrol

Via drug repositioning, Osaka City University creates combination of rifampicin and resveratrol and have shown in mouse models that the nasal administration improves cognitive function without the negative liver side effects of rifampicin alone.

Dementia is thought to occur when proteins called amyloid-β, tau, and α-synuclein accumulate in the brain and form oligomers. A research group from the Department of Translational Neuroscience, Osaka City University Graduate School of Medicine, had previously shown in a study using mice that the antibiotic rifampicin removes oligomers from the brain and improves cognitive function. However, the drug has been associated with side effects such as liver damage. Resveratrol, a naturally occurring antioxidant in plants, is used as a supplement in Europe and the United States.

“To combat the negative side effects of the existing drug rifampicin, we thought of combining it with the hepatoprotective effects of resveratrol,” illustrates Professor Takami Tomiyama, who acted as lead investigator for the current study.

This time, the research group administered a fixed dose combination of rifampicin and resveratrol intranasally five days a week for a total of four weeks to mice models of Alzheimer’s disease, frontotemporal dementia, and dementia with Lewy bodies, and observed their cognitive functions and brain pathology. The results showed that the combination significantly improved the cognitive function of the mice, inhibited the accumulation of oligomers, and restored synaptophysin levels – presynaptic proteins that facilitate synapses. Additionally, blood levels of liver enzymes, a marker of hepatic damage that normally increases with rifampicin, remained normal in the fixed-dose combination. Furthermore, increased levels of brain-derived neurotrophic factor (BDNF) expression were observed in the hippocampus, which was not seen with rifampicin alone. These results indicate that this fixed-dose combination is superior to rifampicin alone in terms of both safety and efficacy.

The results of this study were published online in the Swiss scientific journal Frontiers in Neuroscience on December 13, 2021.

“The number of patients with dementia has been increasing all over the world, with some sources predicting a doubling of patients every 20 years. However, there is still no effective treatment for the disease,” states Specially Appointed Lecturer Tomohiro Umeda, first author of the study. “Recent studies have shown that abnormalities begin to appear in the brains of dementia patients more than 20 years before the onset of the disease.” By investigating new therapeutic purposes with existing drugs in a process called drug repositioning, the research team hopes to diagnose and prevent dementia before the neurons start dying.

Furthermore, based on the team’s previous research experience, nasal administration of a fixed dose combination of rifampicin and resveratrol would increase drug transferability to the brain and further enhance both safety and medicinal effects. The dosage used in this study was 0.02 mg of rifampicin per mouse per day, or 1 mg/kg/day assuming a mouse weight of 20g. “Converted to a human dosage based on body surface area, it becomes 0.081 mg/kg/day,” states Prof. Tomiyama, “currently, rifampicin is prescribed at 10 mg/kg/day as an antibiotic, and compared to this, we confirmed an effect at a much lower dosage.”

The development of a fixed-dose combination of rifampicin and resveratrol nasal spray is currently being carried out by Medilabo RFP, a venture company originating from the research team’s laboratory. Following the publication of this paper, Medilabo RFP has begun preparations for global clinical trials. In November 2021, with the support of the Japan External Trade Organization (JETRO), Medilabo RFP has established a subsidiary in Massachusetts, USA.

Paper Information

Journal: Frontiers in Neuroscience

Article: Oligomer-targeting prevention of neurodegenerative dementia by intranasal rifampicin and resveratrol combination – a preclinical study in model mice

DOI: 10.3389/fnins.2021.763476

Media Contact

James Gracey
E-mail: kokusai[at]ado.osaka-cu.ac.jp
*Please change [at] to @.



from ScienceBlog.com https://ift.tt/3mHGJoe
Labels:

Comments

Post a Comment

Popular posts from this blog

Wiggling worms suggest link between vitamin B12 and Alzheimer’s

Worms don’t wiggle when they have Alzheimer’s disease. Yet something helped worms with the disease hold onto their wiggle in Professor Jessica Tanis’s lab at the University of Delaware. In solving the mystery, Tanis and her team have yielded new clues into the potential impact of diet on Alzheimer’s, the dreaded degenerative brain disease afflicting more than 6 million Americans. A few years ago, Tanis and her team began investigating factors affecting the onset and progression of Alzheimer’s disease. They were doing genetic research with  C. elegans , a tiny soil-dwelling worm that is the subject of numerous studies. Expression of amyloid beta, a toxic protein implicated in Alzheimer’s disease, paralyzes worms within 36 hours after they reach adulthood. While the worms in one petri dish in Tanis’s lab were rendered completely immobile, the worms of the same age in the adjacent petri dish still had their wiggle, documented as “body bends,” by the scientists. “It was an observa...
Post a Comment
Read more

‘Massive-scale mobilization’ necessary for addressing climate change, scientists say

A year after a global coalition of more than 11,000 scientists declared a climate emergency, Oregon State University researchers who initiated the declaration released an update today that points to a handful of hopeful signs, but shares continued alarm regarding an overall lack of progress in addressing climate risks. “Young people in more than 3,500 locations around the world have organized to push for urgent action,” said Oregon State University’s William Ripple, who co-authored “The Climate Emergency: 2020 in Review,” published today in Scientific American. “And the Black Lives Matter movement has elevated social injustice and equality to the top of our consciousness. “Rapid progress in each of the climate action steps we outline is possible if framed from the outset in the context of climate justice – climate change is a deeply moral issue. We desperately need those who face the most severe climate risks to help shape the response.” One year ago, Ripple, distinguished profess...
Post a Comment
Read more

Ancient Shell Sounds

Abandoned at the mouth of your shelter you quivered apprehensively at our approach, crying out to be held as we proclaimed the exception of your discovery. Sighing wearily as we consigned you to the dusty silence of our archives. But now When I hold you in my hands, I see the face of your purposefully speckled complexion. When I lift you to my ear, I hear the sound of an ancient sea lapping at your shores. When I place you at my lips, I feel the heartbeat of your creator pulsing to my breath. I close my eyes, as you call out to all that you have lost. The shell that was recovered from the Marsoulas cave in the Pyrenees of France (Image Credit: C. Fritz, Muséum d’Histoire naturelle de Toulouse). This poem is inspired by recent research , which has discovered that a large seashell that sat in a French museum for decades is actually a musical instrument used around 18,000 years ago. In 1931, researchers working in southern France unearthed a large seashell at the entr...
Post a Comment
Read more